MPLT: the cash flow

MyFinsight

For the year ending 2025-12-31, MPLT had $8,476K increase in cash & cash equivalents over the period. -$138,610K in free cash flow.

Cash Flow	2025-12-31
Net loss	-161,152
Depreciation	578
Stock-based compensation expense	36,006
Net amortization of premiums and accretion of discounts on investments	2,102
Common stock issued to neurosolis, inc	496
Non-cash lease expense	866
Loss on disposal of property and equipment	-7
Prepaid expenses and other assets	13,103
Accounts payable	1,384
Accrued expenses	2,899
Operating lease liabilities	-777
Deferred grant earnings	-3,239
Net cash used in operating activities	-138,137
Purchases of short-term and long-term investments	408,234
Maturities of marketable debt securities	85,500
Purchases of property and equipment	473
Net cash used in investing activities	-323,207
Payments of deferred financing costs	5,021
Proceeds from issuance of series d redeemable convertible preferred stock, net of issuance costs	198,840
Proceeds from initial public offering of common stock and private placement, net of underwriting fees	275,716
Proceeds from exercises of stock options	285
Net cash provided by financing activities	469,820
Increase (decrease) in cash, cash equivalents, and restricted cash	8,476
Cash, cash equivalents, and restricted cash at beginning of period	38,460
Cash, cash equivalents, and restricted cash at end of period	46,936

Unit: Thousand (K) dollars (except for numbers of shares and EPS).